<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512898</url>
  </required_header>
  <id_info>
    <org_study_id>H. Pylori</org_study_id>
    <nct_id>NCT04512898</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study</brief_title>
  <official_title>Effect of Helicobacter Pylori Eradication on Symptoms and Quality of Life of Irritable Bowel Syndrome: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      H. Pylori is frequently observed in patients with irritable bowel syndrome(IBS). However, the&#xD;
      effect of H. pylori eradication on IBS is not clear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with IBS symptoms using Rome IV criteria will be included. Testing for H. pylori&#xD;
      will be done. Patients with H. pylori will receive triple therapy and followed after two&#xD;
      weeks for eradication and assessment of IBS symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2020</start_date>
  <completion_date type="Anticipated">November 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with IBS and have H. pylori</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire for Rome IV criteria</measure>
    <time_frame>2 weeks</time_frame>
    <description>Symptoms of IBS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>Quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Patient with IBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with IBS and positive H. pylori.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple therapy for H.pylori</intervention_name>
    <description>Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.</description>
    <arm_group_label>Patient with IBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients newly diagnosed with IBS and H.pylori&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients received previous treatment of H.pylori&#xD;
&#xD;
          -  Patients receiving treatment for IBS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Haidi Karam</investigator_full_name>
    <investigator_title>Lecturer of Tropical Medicine and Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

